Kurnit KC - Search Results

1

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F. Kurnit KC, et al. Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Clin Cancer Res. 2018. PMID: 29420224 Free PMC article. Review.

2

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.

Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR. Kurnit KC, et al. Mod Pathol. 2017 Jul;30(7):1032-1041. doi: 10.1038/modpathol.2017.15. Epub 2017 Mar 10. Mod Pathol. 2017. PMID: 28281553 Free PMC article.

3

"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.

Kurnit KC, Bailey AM, Zeng J, Johnson AM, Shufean MA, Brusco L, Litzenburger BC, Sánchez NS, Khotskaya YB, Holla V, Simpson A, Mills GB, Mendelsohn J, Bernstam E, Shaw K, Meric-Bernstam F. Kurnit KC, et al. Cancer Res. 2017 Nov 1;77(21):e123-e126. doi: 10.1158/0008-5472.CAN-17-0341. Cancer Res. 2017. PMID: 29092956 Free PMC article.

4

Moving From Mutation to Actionability.

Colombo I, Kurnit KC, Westin SN, Oza AM. Colombo I, et al. Among authors: kurnit kc. Am Soc Clin Oncol Educ Book. 2018 May 23;38:495-503. doi: 10.1200/EDBK_199665. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231353 Free article. Review.

5

Microsatellite instability in endometrial cancer: New purpose for an old test.

Kurnit KC, Westin SN, Coleman RL. Kurnit KC, et al. Cancer. 2019 Jul 1;125(13):2154-2163. doi: 10.1002/cncr.32058. Epub 2019 Mar 26. Cancer. 2019. PMID: 30913308 Free PMC article.

6

Slow and steady wins the race: precision medicine for low risk endometrial cancer.

Kurnit KC, Westin SN. Kurnit KC, et al. Int J Gynecol Cancer. 2020 Jun;30(6):724-725. doi: 10.1136/ijgc-2020-001467. Epub 2020 May 5. Int J Gynecol Cancer. 2020. PMID: 32376741 No abstract available.

7

Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival.

Kurnit KC, Fellman BM, Mills GB, Bowser JL, Xie S, Broaddus RR. Kurnit KC, et al. Int J Gynecol Cancer. 2022 Jul 4;32(7):869-874. doi: 10.1136/ijgc-2021-003340. Int J Gynecol Cancer. 2022. PMID: 35483739 Free PMC article.

8

PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. Kurnit KC, et al. Pharmacol Ther. 2020 Sep;213:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub 2020 May 23. Pharmacol Ther. 2020. PMID: 32450190 Free PMC article. Review.

9

Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.

Kim G, Kurnit KC, Djordjevic B, Singh C, Munsell MF, Wang WL, Lazar AJ, Zhang W, Broaddus R. Kim G, et al. Among authors: kurnit kc. Mod Pathol. 2018 Oct;31(10):1553-1559. doi: 10.1038/s41379-018-0080-0. Epub 2018 May 24. Mod Pathol. 2018. PMID: 29795437 Free PMC article.

10

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Kurnit KC, Coleman RL, Westin SN. Kurnit KC, et al. Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. Curr Treat Options Oncol. 2018. PMID: 30535808 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters